This is shrinking the discount for US pot companies that was exacerbated in January when Attorney General Sessions said he’d reverse an Obama-era policy that helped states legalize recreational marijuana. As more states including Massachusetts and New Jersey push ahead regardless, investors are becoming more comfortable with the sector, buying up Canadian-listed companies with expanding US businesses at the expense of pure-play Canadian pot stocks which had soared until this year.
“All this capital that has been waiting on the sidelines watched what happened in Canada and there’s maybe a little bit of FOMO," said Morgan Paxhia, co-founder and co-manager of Poseidon Asset Management LLC, one of the longest-running hedge funds in the cannabis space.
There’s plenty to miss out on, according to a recent analysis by GMP Securities. At $6 billion in sales, the US pot market is already roughly as large as Canada’s targeted market size in 2022, analyst Robert Fagan wrote in a recent note. Fagan believes US retail sales will reach $20 billion by 2022; that means the Canadian cannabis sector is trading at 6.3 times 2022 sales while the US cannabis sector is trading at just 0.2 times. In aggregate, the US sector could reach a public market value of $50 billion, or 10 times higher than current levels, he said.
Investors are starting to take notice, particularly of the multi-state operators that have exposure to more than one US market. The top performing stock on the BI Canada Cannabis Competitive Peers index is iAnthus Capital Holdings Inc., which owns and operates cultivators, processors and dispensaries in six states. It has gained 144% this year, including an almost 90% increase since the beginning of April.
Green Thumb Industries Inc., which operates in seven states, has gained about 20% since its 13 June trading debut and recently announced an C$80 million ($61 million) bought-deal financing. Pot retailer MedMen Enterprises Inc., with stores in California, Nevada and New York, went public on the Canadian Securities Exchange in May and did a private placement that it said gave it an enterprise valuation of over C$2 billion.
Investors are also snapping up Canadian companies that list on US exchanges, showing growing comfort with the sector as a whole. Based in Nanaimo, British Columbia, Canada-focused Tilray Inc. began trading on the Nasdaq earlier this month and has soared 34 percent since then. Tilray now has a market value of $2.1 billion, trailing only the three biggest Canadian pot stocks.
The US-focused cannabis companies tend to trade on the small Canadian Securities Exchange because US laws prevent them from listing on the big bourses such as New York Stock Exchange and the Toronto Stock Exchange. The CSE currently has 36 listings from US cannabis and cannabis-related firms.
Private companies are attracting big investments too. Acreage Holdings recently raised $119 million, the largest private funding round ever closed by a US cannabis company, according to industry publication Marijuana Business Daily.
“We’re seeing a broader pool of capital show up," said Graham Saunders, head of origination at Canaccord Genuity Group Inc., which last year was the biggest dealmaker in the industry. “We are very busy in the US with a bunch of companies looking for a better cost of capital through the public markets, and we’re seeing a broader audience institutionally for investment into US cannabis-oriented companies."
Growth in the US cannabis industry was hindered until recently by a lack of capital and a lack of qualified people, both prompted by investor discomfort, said iAnthus chief executive officer Hadley Ford, a former investment banker at Goldman Sachs Group Inc. and Bank of America Corp. That has changed with several incremental developments, including President Donald Trump’s endorsement of states’ rights and former speaker of the House John Boehner, once a vocal foe of legalization, joining Acreage Holdings’ board.
“It’s pebbles on the scale," Ford said. “There’s been no big boulder that’s come rolling down the hill but there’s been a lot of little tiny rocks that add up."
Where iAnthus couldn’t even get a meeting with hedge-fund managers four years ago, today they’re seeing interest from “mainline mutual funds," Ford said. “We’re coming up from the bottom of the boiler room to real companies, real names, real analysts."
Canaccord analyst Matt Bottomley said he expects an inflection point in the next two years that will result in a re-rating of US companies, which have an operational advantage over many of their Canadian peers.
For now, the US-focused companies remain small, making it harder for big institutional investors to trade them. New York-based MedMen and Green Thumb of Chicago have market values of less than C$130 million. IAnthus is worth about C$300 million.
“The businesses there are real cash-flowing businesses that are vertically integrated compared to what we’re seeing in Canada, meaning from seed to sale they own all the economics," said Bottomley, whose top pick in the US space is iAnthus. “There certainly is a lot of room for both fundamental accretion in the valuations of these names as well as a valuation re-rating relative to Canadian names. There’s almost an embarrassing amount of opportunity in the US"
For investors, that may mean cutting exposure to Canadian names and adding their US counterparts. Canadian firms such as Canopy Growth Corp. saw their share prices more than triple last year though many have pulled back in 2018, with the BI Canada Cannabis Competitive Peers index down 43%.
The Purpose Marijuana Opportunities Fund, the first actively managed pot exchange-traded fund, has been adding Green Thumb and trimming its holdings of Aurora Cannabis Inc., said portfolio manager Greg Taylor.
“The valuations got a little excessive on a lot of the Canadian companies," Taylor said. “The pendulum is moving in favor of full legalization in the US and I think as that happens, you’re definitely going to close the gap between the valuations."